Stock MNOV MEDICINOVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MediciNova, Inc.

Equities

MNOV

US58468P2065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
1.42 USD -0.70% Intraday chart for MediciNova, Inc. -7.19% -5.33%
May. 14 MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome CI
May. 09 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 295.9 236.3 131.4 100.5 73.57 69.65 - -
Enterprise Value (EV) 1 295.9 176.3 131.4 100.5 73.57 69.65 69.65 69.65
P/E ratio -22.5 x -17 x -12.8 x -7.07 x -8.82 x -6.17 x -5.92 x -5.92 x
Yield - - - - - - - -
Capitalization / Revenue - - 32.6 x - 73.6 x - - -
EV / Revenue - - 32.6 x - 73.6 x - - -
EV / EBITDA - -16,692,748 x - - - - - -
EV / FCF -32,390,079 x -21,754,779 x -13,967,179 x -7,784,172 x - - - -
FCF Yield -0% -0% -0% -0% - - - -
Price to Book 3.95 x 3.32 x - - - - - -
Nbr of stocks (in thousands) 43,906 44,928 49,043 49,046 49,046 49,046 - -
Reference price 2 6.740 5.260 2.680 2.050 1.500 1.420 1.420 1.420
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 4.038 - 1 - - -
EBITDA - -14.16 - - - - - -
EBIT 1 -14.03 -14.18 -10.22 -14.63 -9.9 -11.3 -11.7 -12.1
Operating Margin - - -253.02% - -990.03% - - -
Earnings before Tax (EBT) 1 -12.93 -13.86 -10.13 -14.07 -8.568 -11.3 -11.7 -12.1
Net income 1 -12.94 -13.85 -10.13 -14.07 -8.572 -11.3 -11.7 -12.1
Net margin - - -251% - -857.15% - - -
EPS 2 -0.3000 -0.3100 -0.2100 -0.2900 -0.1700 -0.2300 -0.2400 -0.2400
Free Cash Flow -9.136 -10.86 -9.41 -12.92 - - - -
FCF margin - - -233.07% - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - 1 - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -2.103 -3.41 -4.09 -3.897 -3.231 -2.963 -3.3 -1.147 -2.49 -3.136 -2.8 -2.9 -3
Operating Margin - - - - - - - -114.69% - - - - -
Earnings before Tax (EBT) 1 -2.081 -3.386 -4.029 -3.652 -2.999 -2.918 -2.872 -0.7231 -2.056 -2.755 -2.8 -2.9 -3
Net income 1 -2.083 -3.386 -4.029 -3.652 -3.001 -2.918 -2.872 -0.7231 -2.059 -2.755 -2.8 -2.9 -3
Net margin - - - - - - - -72.31% - - - - -
EPS 2 -0.0400 -0.0700 -0.0800 -0.0700 -0.0600 -0.0600 -0.0600 -0.0100 -0.0400 -0.0600 -0.0600 -0.0600 -0.0600
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/16/22 5/12/22 8/11/22 11/10/22 2/16/23 5/11/23 8/9/23 11/9/23 2/15/24 5/9/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - 60 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -9.14 -10.9 -9.41 -12.9 - - - -
ROE (net income / shareholders' equity) -17.5% -19% - - - - - -
ROA (Net income/ Total Assets) -16.5% -17.9% - - - - - -
Assets 1 78.22 77.31 - - - - - -
Book Value Per Share 1.710 1.580 - - - - - -
Cash Flow per Share - - - - - - - -
Capex 0.01 0.04 0.03 0.01 - - - -
Capex / Sales - - 0.71% - - - - -
Announcement Date 2/13/20 2/19/21 2/16/22 2/16/23 2/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.42 USD
Average target price
17 USD
Spread / Average Target
+1,097.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDICINOVA, INC. Stock MediciNova, Inc.
-5.33% 69.65M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-2.30% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.87B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MNOV Stock
  4. Financials MediciNova, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW